ForsikringsBrief AdvisorBrief KØB SENESTE NYT KURSER Køb Abonnement

Financial Times

Financial Times
Pro Financial Times

What other conditions could weight-loss drugs treat?

According to data provider Airfinity, there are 66 ongoing, late-stage trials of GLP-1 drugs for obesity, diabetes and a range of other conditions linked to excess weight.
According to data provider Airfinity, there are 66 ongoing, late-stage trials of GLP-1 drugs for obesity, diabetes and a range of other conditions linked to excess weight. Foto: Scott Olson/AFP/Ritzau Scanpix
Financial Times

Ian Johnston and Michael Peel in London, Financial Times 
12. dec. 2024 KL. 10.48 Gem til senere

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s

One of Dr Mo Sarhan’s patients was experiencing intense cravings for opioids and alcohol when the Florida-based doctor offered him a striking solution: the Eli Lilly weight-loss drug Mounjaro.

NÆVNTE EMNER: Financial Times

Andre læser også

Forsiden lige nu